A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19 includes research on long-lasting Covid-19 effects seen in children.
Given the current state of events in the world, Klick Health evolved the digital health agency’s annual Little Klickster Day to a virtual format.
DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.
The U.S. Food and Drug Administration approved Vertex Pharmaceuticals Inc.’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko (tezacaftor/ivacaftor and ivacaftor) and Kalydeco (ivacaftor) for use in people with cystic fibrosis with certain rare mutations.
The European Commission approved Aimmune Therapeutics Inc.’s Palforzia for the treatment of peanut allergy.
Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), noted that it would take time – possibly months – before people 18 years of age and younger could get a Covid-19 vaccine because clinical trials were either underway or had not yet begun.
Sanofi and Regeneron’s Dupixent product won approval from the European Commission to treat children aged 6-11 years suffering from severe atopic dermatitis, often known as eczema.
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.
The U.S. Food and Drug Administration approved Eiger BioPharmaceuticals’ Zokinvy for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.
The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health official said.
